On August 20, 2026 RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared drug-delivery device, reported that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company’s patent application (U.S. Application No. 18/184,620) titled "Methods and Apparatuses for Delivery of Therapeutic Materials for the Treatment of Cancer."
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Once issued, this patent will strengthen RenovoRx’s growing U.S. intellectual property portfolio, reinforcing the Company’s differentiated approach to targeted, local drug-delivery, and broadening protection for its TAMP (Trans-Arterial Micro-Perfusion) platform and RenovoCath device.
The newly allowed application further strengthens RenovoRx’s expanding intellectual property portfolio and provides additional patent protection for RenovoCath, an advanced dual-occlusion catheter, designed to deliver cancer therapies directly to targeted tumor sites. The technology is intended to improve the precision and effectiveness of localized therapies while reducing systemic exposure and treatment related side effects compared with conventional drug delivery. The claims allowed cover RenovoCath’s proprietary catheter system, which includes a primary catheter, multiple ports, and expandable occlusion balloons that seal a segment of a blood vessel to create a controlled treatment zone. A secondary catheter can be advanced through the primary catheter into a branching vessel, allowing highly selective access to adjacent vasculature. This configuration enables clinicians to guide both catheters with dedicated guidewires and establish precisely controlled fluid pathways for targeted delivery, further reinforcing RenovoCath’s differentiated technology platform and strengthening its competitive position in precision oncology.
"This Notice of Allowance underscores the continued innovation driving our proprietary TAMP platform and further strengthens the intellectual property foundation supporting RenovoCath and our commercialization strategy," said Shaun Bagai, Chief Executive Officer of RenovoRx. "By extending protection, we are enhancing our competitive differentiation, broadening the potential applications of our platform, and reinforcing our long-term innovation strategy."
Mr. Bagai continued, "Our robust and growing intellectual property portfolio is an important asset as we advance our commercialization of RenovoCath as a standalone device and support our ongoing Phase III TIGeR-PaC clinical trial. Each new allowance further validates the innovative mechanism behind our proprietary TAMP platform and its potential to address limitations of both conventional systemic and local therapeutic drug-delivery."
With this allowance, RenovoRx’s global intellectual property portfolio now includes 20 issued or allowed patents, along, with 13 pending patents, directed to its TAMP platform and RenovoCath device. RenovoRx continues to grow and protect this portfolio in support of its commercialization strategy, including potential partnerships and licensing opportunities.
(Press release, Renovorx, AUG 20, 2026, https://www.globenewswire.com/news-release/2026/08/20/3348338/0/en/renovorx-receives-notice-of-allowance-for-new-u-s-patent-covering-renovocath-an-advanced-dual-occlusion-catheter-for-targeted-therapeutic-drug-delivery-for-cancer-treatment.html [SID1234670264])